.avif)
NSE Test - Lung Cancer Biomarker
The Neuron‑Specific Enolase (NSE) blood test measures a tumor/neuronal injury marker to help detect and monitor neuroendocrine tumors (e.g., small‑cell lung cancer, neuroblastoma) and assess neuronal damage. Early detection and ongoing monitoring can speed diagnosis and treatment decisions, helping prevent cancer progression and complications from neurological injury.
Tumor Mutational Burden Test - Lung Cancer Biomarker
Tumor mutational burden (TMB) testing measures how many genetic mutations are present in a tumor to help predict whether immunotherapy is likely to be effective. By guiding more informed treatment choices, it can help avoid ineffective therapies, unnecessary side effects, and delays in getting the right cancer treatment.
CYFRA 21-1 Test - Lung Cancer Biomarker
CYFRA 21‑1 is a blood test that measures cytokeratin‑19 fragments as a tumor marker to help detect and monitor certain cancers—most commonly non‑small‑cell (especially squamous) lung cancer—and to track treatment response and recurrence. By signaling changes in tumor activity earlier, it can help catch progression or relapse sooner, enabling timelier intervention and potentially better outcomes.
PIK3CA Test - Lung Cancer Biomarker
The PIK3CA test detects mutations in the PIK3CA gene that can drive certain cancers and overgrowth disorders, enabling precise diagnosis and treatment planning. Knowing your PIK3CA status can help clinicians select effective targeted therapies and monitoring strategies, potentially avoiding ineffective treatments and reducing the risk of delayed intervention or disease progression.
HER2 Mutation Test - Lung Cancer Biomarker
A fast genetic test that detects HER2 (ERBB2) amplification or mutations in tumor tissue to identify whether you’re likely to benefit from HER2‑targeted therapies. Knowing your HER2 status helps guide more effective, personalized cancer treatment and may reduce the risk of ineffective therapy, disease progression, or recurrence.
MET Gene Mutation Test - Lung Cancer Biomarker
Detects mutations, amplifications, and fusions in the MET gene—alterations that drive cancers such as non‑small‑cell lung cancer and hereditary papillary renal carcinoma and can identify candidates for MET‑targeted therapies. By revealing actionable MET changes, it helps guide treatment and surveillance decisions, potentially reducing the risk of disease progression or ineffective therapy.
PD-L1 Test - Lung Cancer Biomarker
The PD‑L1 test measures PD‑L1 protein on tumor or immune cells to identify patients likely to benefit from PD‑1/PD‑L1 checkpoint inhibitor immunotherapies. By guiding treatment selection, it can help avoid ineffective therapies, unnecessary side effects, and delays in receiving the most appropriate cancer care.
NTRK Fusion Test - Lung Cancer Biomarker
This NTRK fusion test detects gene rearrangements that create oncogenic TRK fusion proteins present in a range of tumors. Identifying these fusions helps clinicians select effective targeted therapies, reducing the risk of cancer progression and unnecessary treatments.
RET Mutation Test - Lung Cancer Biomarker
Detects inherited RET gene changes that identify people at high risk for medullary thyroid carcinoma and related endocrine tumors (MEN2). Knowing your RET status enables early surveillance and preventive steps—like targeted screening or prophylactic treatment—to reduce the chance of advanced cancer and serious complications.
BRAF Mutation Test - Lung Cancer Biomarker
This BRAF mutation test detects clinically significant changes in the BRAF gene (e.g., V600E) to confirm diagnosis and guide targeted treatment decisions for cancer. By identifying who will benefit from BRAF-targeted therapies, it can help avoid ineffective treatments and reduce the risk of cancer progression or recurrence—particularly in melanoma, colorectal, thyroid, lung cancers and hairy cell leukemia.
ROS1 Fusion Test - Lung Cancer Biomarker
This ROS1 fusion test detects ROS1 gene rearrangements in a patient’s tumor to identify eligibility for ROS1-targeted therapies. By enabling selection of effective targeted treatment, it can help avoid ineffective chemotherapy, unnecessary toxicity, and faster cancer progression.
ALK Gene Test - Lung Cancer Biomarker
This ALK gene test detects inherited or tumor-associated ALK alterations that signal elevated cancer risk or an actionable driver mutation. Knowing your ALK status can enable earlier diagnosis and access to targeted treatments for cancers such as non‑small‑cell lung cancer, anaplastic large‑cell lymphoma, and neuroblastoma, potentially improving outcomes.
KRAS Mutation Test - Lung Cancer Biomarker
Detects mutations in the KRAS gene to inform diagnosis and guide personalized cancer treatment decisions. By identifying actionable KRAS variants, it helps avoid ineffective therapies and supports earlier, targeted care for cancers such as colorectal, non‑small cell lung, and pancreatic cancer.
EGFR Mutation Test - Lung Cancer Biomarker
This EGFR mutation test detects actionable changes in the EGFR gene to guide targeted therapy decisions for patients with non‑small cell lung cancer. By identifying mutations that predict treatment response, it helps avoid ineffective treatments, reduce unnecessary side effects, and support earlier, more effective disease management.
.svg)
